NEW YORK, Jan. 22, 2025 /PRNewswire/ — Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the fourth quarter and year ended December 31, 2024. The earnings release along with the accompanying earnings presentation can be viewed at Cohen & Steers Reports Results for Fourth Quarter and Year Ended December 31, 2024 and on the company’s website at www.cohenandsteers.com under “Company—Investor Relations—Earnings Archive.”

Conference Call

The company will host a conference call tomorrow, Thursday, January 23, 2025, at 10:00 a.m. (ET) to discuss these results via webcast and telephone. Hosting the call will be chief executive officer, Joseph Harvey, chief financial officer, Raja Dakkuri, and head of multi-asset solutions, Jeffrey Palma.

Investors and analysts can access the live conference call by dialing 800-715-9871 (U.S.) or +1-646-307-1963 (international); passcode: 8494569. Participants should plan to register at least 10 minutes before the conference call begins. A replay of the call will be available for two weeks starting approximately two hours after the conference call concludes and can be accessed at 800-770-2030 (U.S.) or +1-609-800-9909 (international); passcode: 8494569. Internet access to the webcast, which includes audio (listen-only), will be available on the company’s website at www.cohenandsteers.com under “Company—Investor Relations” under “Financials.” The webcast will be archived on the website for one month.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

View original content:https://www.prnewswire.com/news-releases/cohen–steers-reports-results-for-fourth-quarter-and-year-ended-december-31-2024-302357884.html

SOURCE Cohen & Steers, Inc.

ATLANTA, Jan. 22, 2025 /PRNewswire/ — Equifax® (NYSE: EFX) will announce its financial results for the fourth quarter ended December 31, 2024, in a release to be issued on Thursday, February 6, at 6:30 a.m. Eastern Time (ET).

Equifax will host a conference call at 8:30 a.m. ET on February 6, in which senior management will discuss financial and business results for the quarter. Related presentation materials will be published on investor.equifax.com on February 6 at 6:30 a.m. ET.

Conference Call:  
US/Canada: 877-559-1190 / +1 201-389-0916
International: Click here for participant International Toll-Free access numbers

Please dial the appropriate number 5-10 minutes prior to the call to complete registration. Name and affiliation/company are required to join the call.

Webcast:
To view the webcast and slide presentation, please click the link and enter your information to be connected. The link becomes active 15 minutes prior to the scheduled start time.

An audio replay of the conference call will be available on investor.equifax.com beginning on February 7.

ABOUT EQUIFAX INC.
At Equifax (NYSE: EFX), we believe knowledge drives progress. As a global data, analytics, and technology company, we play an essential role in the global economy by helping financial institutions, companies, employers, and government agencies make critical decisions with greater confidence. Our unique blend of differentiated data, analytics, and cloud technology drives insights to power decisions to move people forward. Headquartered in Atlanta and supported by nearly 15,000 employees worldwide, Equifax operates or has investments in 24 countries in North America, Central and South America, Europe, and the Asia Pacific region. For more information, visit Equifax.com.

FOR MORE INFORMATION:
Molly Clegg for Equifax
molly.clegg@equifax.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/equifax-announces-earnings-release-date-and-conference-call-for-fourth-quarter-2024-results-302357665.html

SOURCE Equifax Inc.

NORTON, Va., LA ROCHELLE, France and BUDAPEST, Hungary, Jan. 22, 2025 /PRNewswire/ — Today, SOLARBIOTECH, GPC Bio, and Eleszto Genetika proudly announced their acquisition and strategic unification under a single ownership. 

This consolidation creates a vertically integrated Synthetic Biology and Biomanufacturing powerhouse, uniquely positioned to harness the disruptive potential of precision fermentation. By integrating decades of expertise, the unified organization will leverage the strength of each team to seamlessly advance Synthetic Biology innovation from ideation to commercial production.

The acquisitions bring together over 100 engineers, scientists, and seasoned biotech executives, marking a significant leap forward in the rapidly evolving biomanufacturing landscape. The unified organization is fully equipped to give clients unparalleled and seamless support in all stages of biomanufacturing, including microbial strain and bioprocess development, plant engineering, automation, construction, deployment, and large-scale operations. The coming months will involve further integrational activities to fully leverage the strength of the organization.

Strategic Relevance

“The challenges of microbial strain engineering often hindered by restrictive intellectual property and the technical hurdles of scaling bioprocesses, have long impeded the faster development of synthetic biology products. By uniting these companies, we can directly address these challenges head-on, transforming the biomanufacturing landscape with the financial and operational support necessary for growth,” said Alex Berlin, CEO of Pictor Biotech Inc. (d.b.a. SOLARBIOTECH).

Zsolt Popsé, CEO of GPC Bio, added, “With nearly 20 years of experience in designing, engineering, automating, and deploying biomanufacturing equipment, we have delivered world-class facilities for leading biopharmaceutical companies such as Merck, Sanofi, and Millipore-Sigma, as well as major food and beverage companies like Cargill, Groupe Soufflet, and Lesaffre. The integration of GPC Bio with EG and SOLARBIOTECH places us in a unique position to mitigate risk and accelerate growth in the biomanufacturing space.”

Lóránd Szabó, Managing Director of Eleszto Genetika Kft., stated, “Over the past two decades, we have developed hundreds of microbial strains for the production of biopharmaceuticals, nutraceuticals, and cosmeceuticals. By joining forces with Solar Biotech and GPC Bio, we can efficiently transition products from laboratory scale to commercial production, overcoming the typical hurdles faced by non-integrated organizations.”

Peter Rosholm, owner of EG, GPC Bio and Pictor Biotech (dba SOLARBIOTECH) emphasized: “I am fully committed to investing in and to accelerate the commercial development of sustainable biomanufacturing technologies. By combining SOLARBIOTECH, GPC Bio, and EG under one umbrella, we are uniquely positioning our teams to thrive in this rapidly growing sector. We have a strong, client-focused and diverse organization with very experienced management, and this commitment adds significant funding to the existing companies’ infrastructure.”

About the Companies

Executive Management of the three companies will continue to serve in their respective leadership roles. Peter Rosholm will exclusively serve the organization from an owner and investor capacity.

SOLARBIOTECH (“SBC”), based in Norton, VA, USA, offers world-class expertise in microbial and animal and plant cell precision fermentation and downstream processing across various scales. Leveraging 18 acres of industrial park infrastructure in Southwest Virginia, SBC consistently delivers innovative synthetic biology bioprocesses and products for its partners. 

GPC Bio (“GPC”), headquartered in La Rochelle, France, specializes in the design, automation, software control, engineering, and fabrication of biomanufacturing equipment for the biopharmaceutical, food tech, and beverage industries. For nearly two decades, GPC Bio has delivered state-of-the-art systems to some of the biggest names in industrial biotech and biopharma.

Eleszto Genetika Kft. (“EG”), based in Budapest, Hungary, brings nearly two decades of expertise in R&D for advanced industrial microbial strains. EG’s portfolio includes microbial strains from engineered yeasts, bacteria, and filamentous fungi for producing a wide range of biopharmaceuticals, nutraceuticals, and cosmeceuticals, supported by cutting-edge infrastructure in the heart of the European Union.

For Further Information, Please Contact:

Alex Berlin, CEO & CTO, Pictor Biotech Inc. (d.b.a. SOLARBIOTECH), alex@solarbiotech.com, www.solarbiotech.comZsolt Popsé, CEO of GPC Bio, z.popse@gpcbio.com, www.gpcbio.comLóránd Szabó, Managing Director, Eleszto Genetika Kft., lszabo@elesztogenetika.com, www.elesztogenetika.com

View original content:https://www.prnewswire.com/news-releases/pictor-biotech-inc-dba-solarbiotech-gpc-bio-and-eleszto-genetika-announce-strategic-unification-302357893.html

SOURCE Pictor Biotech Inc. (dba SOLARBIOTECH), GPC Bio, and Eleszto Genetika